a: TP53 pathogenic variants in cases. b: TP53 VUS in cases. (DOCX 20 kb

Arora, Iteeka

Clifford, Angela

Gillett, Cheryl

Megalios, Anargyros

Mera, Anca

Moss, Charlotte

Petridis, Christos

Pinder, Sarah E.

Roylance, Rebecca

Sawyer, Elinor J.

Shah, Vandna

Simpson, Michael A.

Tomlinson, Ian P.

Amplicons that failed to amplify consistently. (DOCX 19 kb

Christos Petridis (553688)

Iteeka Arora (6669857)

Vandna Shah (3661897)

Anargyros Megalios (6669863)

Charlotte Moss (6669866)

Anca Mera (4513309)

Angela Clifford (6669869)

Cheryl Gillett (553699)

Sarah Pinder (553692)

Ian Tomlinson (146463)

Rebecca Roylance (553687)

Michael Simpson (2990385)

Elinor Sawyer (146459)

FigShare

Additional file 4: of Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50âyears

Introduction: Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive ductal breast cancer and approximately 20% of screen-detected tumors are pure DCIS. Most risk factors for breast cancer have similar associations with DCIS and IDC, however there is limited data on the prevalence of the known high and moderate penetrance breast cancer predisposition genes in DCIS and which women with DCIS should be referred for genetic screening.The aim of this study was to assess the frequency of germline variants in BRCA2, BRCA1, CHEK2, PALB2 and TP53 in DCIS in women aged less than 50 years of age.Methods: After DNA extraction from peripheral blood, Access Array technology (Fluidigm) was used to amplify all exons of these six known breast cancer predisposition genes using a custom made targeted sequencing panel in 655 cases of pure DCIS presenting in women under the age of 50 years together with 1,611 controls.Results: Case-control analysis revealed an excess of pathogenic variants in BRCA2 (OR = 27.96, 95%CI 6.56-119.26, P = 2.0 x10-10) and CHEK2 (OR = 8.04, 95%CI 2.93-22.05, P = 9.0 x10-6), with weaker associations with PALB2 (P = 0.003), BRCA1 (P = 0.007) and TP53 (P = 0.02). For estrogen receptor (ER) positive DCIS the frequency of pathogenic variants was 9% under the age of 50 (14% with a family history of breast cancer) and 29% under the age of 40 (42% with a family history of breast cancer). For ER negative DCIS the frequency was 9% (16% with a family history of breast cancer) and 8% (11% with a family history of breast cancer) under the age of 50 and 40 respectively.Conclusions: This study has shown that breast tumorigenesis in women with pathogenic variants in BRCA2, CHEK2, PALB2, BRCA1 and TP53 can involve a DCIS precursor stage and that the focus of genetic testing in DCIS should be on women under the age of 40 with ER positive DCIS.<br/

Pinder, Sarah E

Tomlinson, Ian

Simpson, Michael A

Sawyer, Elinor J

King's Research Portal

English

Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years

INTRODUCTION: Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive ductal breast cancer, and approximately 20% of screen-detected tumours are pure DCIS. Most risk factors for breast cancer have similar associations with DCIS and IDC; however, there is limited data on the prevalence of the known high and moderate penetrance breast cancer predisposition genes in DCIS and which women with DCIS should be referred for genetic screening. The aim of this study was to assess the frequency of germline variants in BRCA2, BRCA1, CHEK2, PALB2 and TP53 in DCIS in women aged less than 50 years of age.METHODS: After DNA extraction from the peripheral blood, Access Array technology (Fluidigm) was used to amplify all exons of these five known breast cancer predisposition genes using a custom made targeted sequencing panel in 655 cases of pure DCIS presenting in women under the age of 50 years together with 1611 controls.RESULTS: Case-control analysis revealed an excess of pathogenic variants in BRCA2 (OR = 27.96, 95%CI 6.56-119.26, P = 2.0 × 10-10) and CHEK2 (OR = 8.04, 95%CI 2.93-22.05, P = 9.0 × 10-6), with weaker associations with PALB2 (P = 0.003), BRCA1 (P = 0.007) and TP53 (P = 0.02). For oestrogen receptor (ER)-positive DCIS the frequency of pathogenic variants was 9% under the age of 50 (14% with a family history of breast cancer) and 29% under the age of 40 (42% with a family history of breast cancer). For ER-negative DCIS, the frequency was 9% (16% with a family history of breast cancer) and 8% (11% with a family history of breast cancer) under the ages of 50 and 40, respectively.CONCLUSIONS: This study has shown that breast tumourigenesis in women with pathogenic variants in BRCA2, CHEK2, PALB2, BRCA1 and TP53 can involve a DCIS precursor stage and that the focus of genetic testing in DCIS should be on women under the age of 40 with ER-positive DCIS.</p

University of Birmingham Research Portal

Edinburgh Research Explorer

BRCA2 pathogenic variants in cases. (DOCX 21 kb

Additional file 6: of Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50âyears

Additional file 10: of Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50âyears

https://kclpure.kcl.ac.uk/portal/files/108842684/Breast_Cancer_Research_DCIS_rare_variant_paper_Feb2019R2_1_.pdf

Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years

Abstract

Similar works

Full text

Available Versions

FigShare

King's Research Portal

University of Birmingham Research Portal

Edinburgh Research Explorer

University of Birmingham Research Portal

FigShare

FigShare